1. WHO. Obesity: Preventing and managing the global epidemic. WHO; Geneva: 1998.
2. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. National Institutes of Health. Obes Res. 1998;6(Suppl 2):51S–209S. [No authors listed] [PubMed]
3. National Heart, Lung, and Blood Institute (NHLBI) and the North American Association for the Study of Obesity (NAASO) The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. National Institutes of Health; Bethesda, MD: 2000.
4. Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention of metformin. N Engl J Med. 2002;346:393–403. [PMC free article] [PubMed] 5. Tuomilehto J, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–1350. [PubMed] 6. Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results from the Look AHEAD trial. Diabetes Care. 2007;30:1374–1383. [PMC free article] [PubMed] 7. Look AHEAD Research Group. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity. 2006;14:737–752. [PMC free article] [PubMed]
8. Wing RR. Reduction in weight and cardiovascular disease (CVD) risk factors in subjects with type 2 diabetes (T2DM): four-year results of Look AHEAD [abstract 06-0R] Obesity. 2009;17 (Suppl 2):S49.
9. Wadden TA, Foster GD. Behavioral treatment of obesity. Med Clin North Am. 2000;84:441–461. [PubMed] 10. Wadden TA, Butryn ML, Wilson C. Lifestyle modification for the management of obesity. Gastroenterology. 2007;132:2226–2238. [PubMed] 11. Renjilian DA, et al. Individual versus group therapy for obesity: effects of matching participants to their treatment preferences. J Consult Clin Psychol. 2001;69:717–721. [PubMed] 12. Tate DF, Wing RR, Winett RA. Using internet technology to deliver a behavioral weight loss program. JAMA. 2001;285:1172–1177. [PubMed] 13. Rothert K, et al. Web-based weight management programs in an integrated health care setting: a randomized, controlled trial. Obesity. 2006;14:266–272. [PubMed] 14. Tate DF, Jackvony EH, Wing RR. A randomized trial comparing human e-mail counseling, computer-automated tailored counseling, and no counseling in an Internet weight loss program. Arch Intern Med. 2006;166:1620–1625. [PubMed] 15. Harvey-Berino J, et al. Does using the Internet facilitate the maintenance of weight loss? Int J Obes Relat Disord. 2002;26:1254–1260. [PubMed]
16. Departments of Agriculture and Health and Human Services. Dietary Guidelines for Americans. US Department of Agriculture, US Department of Health and Human Services; Washington, DC: 2005.
17. Diabetes Prevention Program Research Group. The Diabetes Prevention Program: description of lifestyle intervention. Diabetes Care. 2002;25:2165–2171. [PMC free article] [PubMed]
18. Brownell KD. The LEARN Program for Weight Management. American Health Publishing; Dallas, TX: 2000.
19. Samaha FF, et al. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med. 2003;348:2074–2081. [PubMed] 20. Nordmann AJ, et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:285–293. [PubMed] 21. Brand Miller J, Hayne S, Petocz P, Colagiuri S. Low-glycemic index diets in the management of diabetes. Diabetes Care. 2003;26:2261–2267. [PubMed] 22. Thomas DE, Elliott EJ, Baur L. Cochrane Database of Systematic Reviews. 3. 2007. Low glycaemic index or low glycaemic load diets for overweight and obesity. Art No.: CD005105. [PubMed] [Cross Ref] 23. Shai I, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008;359:229–241. [PubMed] 24. Esposito K, et al. Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial. Ann Intern Med. 2009;151:306–314. [PubMed] 25. Buckland G, Bach A, Serra-Majem L. Obesity and the Mediterranean diet: a systematic review of observational and intervention studies. Obes Rev. 2008;9:582–593. [PubMed] 26. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss: a randomized trial. JAMA. 2005;293:43–53. [PubMed] 27. Sacks FM, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360:859–873. [PMC free article] [PubMed] 28. Fung TT, et al. Mediterranean diet and incidence of and mortality from coronary heart disease and stroke in women. Circulation. 2009;119:1093–1100. [PMC free article] [PubMed]
29. Blair SN, Leermakers EA. In: Handbook of Obesity Treatment. Wadden TA, Stunkard AJ, editors. Guilford Press; New York: 2002. pp. 283–300.
30. Haskell WL, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc. 2007;39:1423–1434. [PubMed] 31. Lee CD, Blair SN, Jackson AS. Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men. Am J Clin Nutr. 1999;69:373–380. [PubMed] 32. Stevens J, Cai J, Evenson KR, Thomas R. Fitness and fatness as predictors of mortality from all causes and from cardiovascular disease in men and women in the lipid research clinics study. Am J Epidemiol. 2002;156:832–841. [PubMed] 33. Hu FB, et al. Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med. 2004;351:2694–2703. [PubMed] 34. Donnelly JE, et al. American College of Sports Medicine position stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc. 2009;41:459–471. [PubMed] 35. Bweir S, et al. Resistance exercise training lowers HbA1c more than aerobic training in adults with type 2 diabetes. Diabetol Metab Syndr. 2009;10:27. [PMC free article] [PubMed] 36. Jakicic JM, Donnelly JE, Pronk NP, Jawad AF, Jacobsen DJ. Prescription of exercise intensity for the obese patient: the relationship between heart rate, VO2, and perceived exertion. Int J Obes Relat Metab Disord. 1995;19:382–387. [PubMed] 37. Jakicic JM, Winters C, Lang W, Wing RR. Effects of intermittent exercise and use of home exercise equipment on adherence, weight loss, and fitness in overweight women: a randomized trial. JAMA. 1999;282:1554–1560. [PubMed] 38. Andersen RE, et al. Effects of lifestyle activity vs structured aerobic exercise in obese women: a randomized trial. JAMA. 1999;281:335–340. [PubMed] 39. Dunn AL, et al. Comparison of lifestyle and structured interventions to increase physical activity and cardiorespiratory fitness: a randomized trial. JAMA. 1999;281:327–334. [PubMed] 40. Bravata DM, et al. Using pedometers to increase physical activity and improve health: a systematic review. JAMA. 2007;298:2296–2304. [PubMed]
41. Brownell KD, Horgen KB. Food Fight: The Inside Story of America’s Obesity Crisis and What We Can Do About It. Contemporary Books; Chicago: 2003.
42. Rosenbaum M, et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest. 2005;115:3579–3586. [PMC free article] [PubMed] 43. Svetkey LP, et al. Comparison of strategies for sustaining weight loss: the weight loss maintenance randomized controlled trial. JAMA. 2008;299:1139–1148. [PubMed] 44. Perri MG, et al. Effects of four maintenance programs on the long-term management of obesity. J Consult Clin Psychol. 1988;56:529–534. [PubMed] 45. Wing RR, Tate DF, Gorin AA, Raynor HA, Fava JL. A self-regulation program for maintenance of weight loss. N Engl J Med. 2006;355:1563–1571. [PubMed] 46. Jeffery RW, Wing RR, Sherwood NE, Tate DF. Physical activity and weight loss: does prescribing higher physical activity goals improve outcome? Am J Clin Nutr. 2003;78:684–689. [PubMed] 47. Wing RR, Hill JO. Successful weight loss maintenance. Annu Rev Nutr. 2001;21:323–341. [PubMed] 48. Wadden TA, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353:2111–2120. [PubMed] 49. James WP, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group Sibutramine Trial of Obesity Reduction and Maintenance. Lancet. 2000;356:2119–2125. [PubMed] 50. Sjostrom L, et al. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicenter Orlistat Study Group. Lancet. 1998;352:167–172. [PubMed] 51. Davidson MH, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281:235–242. [PubMed] 52. Bray GA, Ryan DH. Drug treatment of the overweight patient. Gastroenterology. 2007;132:2239–2252. [PubMed] 53. Lee M, Aronne LJ. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. Am J Cardiol. 2007;99 (Suppl):68B–79B. [PubMed] 54. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335:1194–1199. [PMC free article] [PubMed] 55. Filippatos TD, et al. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf. 2008;31:53–65. [PubMed] 57. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes in the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–161. [PubMed] 58. Digenio AG, Mancuso JP, Gerber RA, Dvorak RV. Comparison of methods for delivering a lifestyle modification program for obese patients: a randomized trial. Ann Int Med. 2009;150:255–262. [PubMed] 59. Wadden TA, et al. Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med. 2001;161:218–27. [PubMed] 60. Torp-Pedersen C, et al. Cardiovascular response to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J. 2007;28:2915–2923. [PubMed] 63. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord. 2002;26:262–273. [PubMed] 64. Munro JF, MacCuish AC, Wilson EM, Duncan LJ. Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J. 1968;1:352–354. [PMC free article] [PubMed]
65. Bray GA, Greenway FL. In: Treatment of the Obese Patient. Kushner RF, Bessesen DH, editors. Humana Press; New Jersey: 2007. pp. 341–368.
66. Connolly HM, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581–588. [PubMed] 67. Li Z, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532–546. [PubMed] 68. Jones D. Novel pharmacotherapies for obesity poised to enter the market. Nat Rev Drug Discov. 2009;8:833–834. [PubMed] 69. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell. 2004;116:337–350. [PubMed] 70. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature. 2006;443:289–295. [PubMed] 71. Ahima RS, Flier JS. Leptin. Annu Rev Physiol. 2000;62:413–437. [PubMed] 72. Greenway FL, et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab. 2009;94:4898–4906. [PubMed]
73. Wadden TA, et al. Weight loss with naltrexone SR/buprobion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. in press.
74. Oommen KJ, Mathews S. Zonisamide: a new antiepileptic drug. Clin Neuropharmacol. 1999;22:192–200. [PubMed] 75. Gadde KM, Franciscy DM, Wagner HR, Krishnan KR. Zonisamide for weight reduction in obese adults: a randomized controlled trial. JAMA. 2003;289:1820–1825. [PubMed]
76. Landbloom R, et al. Long term weight loss from a dose optimization study with zonisamide SR and bupropion SR [abstract 61-OR] Obesity. 2008;16 (Suppl 1):S63–S64.
77. Gadde KM, et al. A 24-week randomized controlled trial of VO-0521, a combination weight loss therapy, in obese adults [abstract 55-OR] Obes Res. 2006;14:A17.
78. Aronne LJ, et al. Weight loss with VI-0521 (phentermine/controlled release topiramate) stops progression toward type 2 diabetes in obese non-diabetic subjects. Diabetes. 2009;58:A32.
79. Gadde KM, Allison DB. Combination therapy for obesity and metabolic disease. Curr Opin Endocrinol Diabetes Obes. 2009;16:353–358. [PubMed] 80. Astrup A, et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res. 2004;12:1658–1669. [PubMed] 81. Roth JD, et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA. 2008;105:7257–7262. [PubMed] 82. Trevaskis JL, et al. Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. Endocrinology. 2008;149:5679–5687. [PubMed] 83. Ravussin E, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity. 2009;17:1736–1743. [PMC free article] [PubMed] 84. Smith SR, et al. Effect of APD356, a selective 5-HT-2C agonist, on weight loss in a 4-week study of healthy obese patients [abstract] Obes Res. 2005;13 (Suppl):A1–218. [PubMed]
85. Smith SR, Prosser W, Donahue D, Anderson CM, Shanahan W. APD356, an orally-selective 5-HT-2C agonist, reduces body weight in obese adult men and women [abstract] Diabetes. 2006;55 (Suppl 1):A80.
86. Thomsen WJ, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine 2c agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther. 2008;325:577–587. [PubMed]
87. Smith SR, Weissman NJ, Scott S, Anderson CM, Shanahan WR. Lorcaserin reduces body weight in obese and overweight subjects: behavioral modification and lorcaserin for overweight and obesity management, the BLOOM trial. American Diabetes Association (ADA) 69th Annual Scientific Sessions; 2009. Abstract 96-LB.
88. Maes HH, Neale MC, Eaves LJ. Genetic and environmental factors in relative body weight and human adiposity. Behav Genet. 1997;27:325–341. [PubMed] 89. Wardle J, Carnell S, Haworth CM, Plomin R. Evidence for a strong genetic influence on childhood adiposity despite the force of the obesogenic environment. Am J Clin Nutr. 2006;87:398–404. [PubMed] 90. Stunkard AJ, et al. An adoption study of human obesity. N Engl J Med. 1986;314:193–198. [PubMed] 91. Vogler GP, Sørensen TI, Stunkard AJ, Srinivasan MR, Rao DC. Influences of genes and shared family environment on adult body mass assessed in an adoption study by a comprehensive path model. Int J Obes Relat Metab Disord. 1995;19:40–45. [PubMed] 92. Hainer V, et al. Role of hereditary factors in weight loss and its maintenance. Physiol Res. 2008;57 (Suppl 1):S1–15. [PubMed] 93. Blakemore AI, Froguel P. Is obesity our genetic legacy? J Clin Endocrinol Metab. 2008;93 (Suppl 1):S51–S56. [PubMed] 94. Dhillon H, et al. Long-term differential modulation of genes encoding orexigenic and anorexigenic peptides by leptin delivered by rAAV vector in ob/ob mice. Relationship with body weight change. Regul Pep. 2000;92:97–105. [PubMed] 95. Li G, Mobbs CV, Scarpace PJ. Central pro-opiomelanocortin gene delivery results in hypophagia, reduced visceral adiposity, and improved insulin sensitivity in genetically obese Zucker rats. Diabetes. 2003;52:1951–1957. [PubMed] 96. Kalra SP, Kalra PS. Gene-transfer technology: a preventive neurotherapy to curb obesity, ameliorate metabolic syndrome and extend life expectancy. Trends Pharmacol Sci. 2005;26:488–95. [PubMed] 97. Ranadive SA, Vaisse C. Lessons from extreme human obesity monogenic disorders. Endocrinol Metab Clin North Am. 2008;37:733–751. [PubMed] 98. Stutzmann F, et al. Prevalence of melanocortin-4 receptor deficiency in Europeans and their age-dependent penetrance in multigenerational pedigrees. Diabetes. 2008;57:2511–2518. [PMC free article] [PubMed] 99. Farooqi IS, et al. Clinical spectrum of obesity and mutations in the melanocortin-4 receptor gene. N Engl J Med. 2003;348:1085–1095. [PubMed] 100. Li S, Loos RJ. Progress in the genetics of common obesity: size matters. Curr Opin Lipidol. 2008;19:113–121. [PubMed] 101. De Krom M, et al. Common genetic variations in CKK, leptin, and leptin receptor genes are associated with specific human eating patterns. Diabetes. 2007;56:276–280. [PubMed] 102. Frayling TM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316:889–894. [PMC free article] [PubMed] 103. Cecil JE, Tavendale R, Watt P, Hetherington MM, Palmer CN. An obesity-associated FTO gene variant and increased energy intake in children. N Engl J Med. 2008;359:2558–2566. [PubMed] 104. Haupt A, et al. Variation in the FTO gene influences food intake but not energy expenditure. Exp Clin Endocrinol Diabetes. 2009;117:194–197. [PubMed] 105. Speakman JR, Rance KA, Johnstone AM. Polymorphisms of the FTO gene are association with a variation in energy intake, but not energy expenditure. Obesity. 2008;16:1961–1965. [PubMed] 106. Timpson NJ, et al. The fat mass- and obesity-associated locus and dietary intake in children. Am J Clin Nutr. 2008;88:971–978. [PubMed] 107. Gerken T, et al. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science. 2007;318:1469–1472. [PMC free article] [PubMed] 108. Tung YCL, et al. Hypothalamic-specific manipulation of Fto, the ortholog of the human obesity gene FTO, affects food intake in rats. PLoS One. 2010;5:e8771. [PMC free article] [PubMed] 109. Loos RJ, et al. Common variants near MC4R are associated with fat mass, weight, and risk of obesity. Nat Genet. 2008;40:768–775. [PMC free article] [PubMed] 110. Willer CJ, et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet. 2009;41:25–34. [PMC free article] [PubMed] 111. Thorleifsson G, et al. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat Genet. 2009;41:18–24. [PubMed] 112. Meyre D, et al. Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. Nat Genet. 2009;41:157–159. [PubMed] 113. Hofker M, Wijmenga C. A supersized list of obesity genes. Nat Genet. 2009;41:139–140. [PubMed] 114. Zolotukhin S. Gene therapy for obesity. Expert Opin Biol Ther. 2005;5:347–357. [PubMed]
115. Ahima RS. Obesity gene therapy: slimming immature rats. Gene Therapy. 2003;10:196–197.
116. Barsh GS, Schwartz MW. Genetic approaches to studying energy balance: perception and integration. Nat Rev Genet. 2002;3:589–600. [PubMed] 117. Gardner CD, et al. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. JAMA. 2007;297:969–77. [PubMed] 118. Stern L, et al. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med. 2004;140:778–85. [PubMed] 119. Foster GD, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med. 2003;348:2082–90. [PubMed] 120. Yancy WS, et al. A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann Intern Med. 2004;140:769–77. [PubMed] 121. Brinkworth GD, et al. Long-term effects of advice to consume a high-protein, low-fat diet, rather than a conventional weight-loss diet, in obese adults with type 2 diabetes: one-year follow-up of a randomised trial. Diabetologia. 2004;47:1677–86. [PubMed]
122. Iqbal N, et al. Effects of a low-intensity intervention that prescribed a low-carbohydrate vs. a low-fat diet in obese, diabetic participants. Obesity. 2009 Epub ahead of print.
123. Klemsdal TO, et al. Effects of a low glycemic load diet versus a low-fat diet in subjects with and without the metabolic syndrome. Nutr Metab Cardiovasc Dis. 2010;20:195–201. [PubMed] 124. Das SK, et al. Long-term effects of 2 energy-restricted diets differing in glycemic load on dietary adherence, body composition, and metabolism in CALERIE: a 1-y randomized controlled trial. Am J Clin Nutr. 2007;85:1023–30. [PubMed] 125. Estruch R, et al. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med. 2006;145:1–11. [PubMed] 126. Brehm BJ, et al. One-year comparison of a high-monounsaturated fat diet with a high-carbohydrate diet in type 2 diabetes. Diabetes Care. 2009;32:215–20. [PMC free article] [PubMed]